Latest news
PCI Biotech to present Phase I fimaVACC results at ESMO Immuno-Oncology 2019
Oslo, Norway, December 12, 2019 PCI Biotech (OSE:PCIB), a clinical-stage company developing innovative therapeutics that address significant unmet medical needs, today announced that it will present results from the successful fimaVacc Phase I proof of concept study in healthy volunteers at the ESMO Immuno-Oncology Congress 2019 being held December 11-14, 2019 at Palexpo in Geneva, Switzerland. […]
PCI Biotech: Third quarter 2019 results
Oslo (Norway), 27 November 2019 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company today announces its third quarter 2019 result. Please find enclosed the report and presentation. Highlights fimaChem *Start-up activities for the RELEASE study are progressing well after the study commenced with enrolment of the first patient in May 2019 *23 out […]
PCI Biotech: Expansion of preclinical research collaboration agreement with AstraZeneca
Oslo (Norway), 26 November 2019 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announced an expansion of its preclinical research collaboration with AstraZeneca. The collaboration was initiated in September 2015 to determine whether PCI Biotech’s fimaNAc technology has the potential to enhance the delivery of AstraZeneca’s nucleic acid therapeutic compounds. The aim […]